the patients with UC and 22.8% with CD were in remission. No significant HRQoL differences were found between UC and CD patients. But, there was a tendency of the CD patients to have higher IBDQ scores and better emotional functioning. ANOVA analysis identified disease activity and symptom’s to explain variations in HRQoL. No significant impact found for sex, educational level, employment and marital status. In contrast, young age (20–40 years) in the CD group had negative impact on their social functioning.

**Conclusion**

HRQoL did not differ significantly between patients with CD and UC. But, there was a tendency of the CD patients to score higher in the IBDQ compared to the UC group which can be justified by the beneficial effect of biologic agents in the management of CD. Young age in CD patients had negative impact on their social functioning which indicates the need for developing supportive networks similar to those of Northern Europe in the South. Finally, disease activity and symptom’s severity were the only factors that affect HRQoL in our population.

**Competing interests**

None declared.

**REFERENCES**


**DEVELOPING SWANSEA INFLAMMATORY BOWEL DISEASE CLINICAL SEVERITY INDEX (SICSI)**

doi:10.1136/gutjnl-2012-302514c.100

L Alrubaiy,* J Williams, H Hutchings. Swansea University, Swansea, UK

**Introduction**

To assess IBD activity, many severity scales have been developed. Yet, most of them were not properly validated and did not go through robust methodology. Using different scoring systems makes it difficult to compare different trials especially when the end points are different. Because new therapies for IBD are rapidly emerging, there is a need to optimise and standardise methodology for assessing of disease activity in clinical trials. With the nationwide initiative to establish an IBD registry, a valid and easy to use activity measurement tool is needed. We believe that having a single wide initiative to establish an IBD registry, a valid and easy to use tool is needed. We believe that having a single tool to assess the clinical activity of IBD. It is valid, reliable, user friendly and non-invasive index. Further studies are required to check how it performs on a wider range of patients.

**Competing interests**

None declared.

**DRUGS USED IN THE TREATMENT OF FISTULAE IN CROHN’S DISEASE PRESERVE MESENCHYMAL STEM CELL SURVIVAL**

doi:10.1136/gutjnl-2012-302514c.101

1. L Meran, a H Rashidi, c H Jones, b R Rose, d K Shakesheff, e C Hawkey. 1Nottingham Digestive Diseases Centre, Nottingham University Hospitals, Nottingham, UK; 2Tissue Engineering, STEM group, Centre for Biomolecular Sciences, Nottingham, UK; 3Department of Immunology, Nottingham University Hospitals, Nottingham, UK

**Introduction**

Mesenchymal stem cells (MSCs) may enhance tissue healing in fistulae of Crohn’s disease, owing to their multilineage differentiation and immunosuppressive capacity. They are currently under investigation in clinical trials in patients with fistulae, whether cryptoglandular in origin or associated with Crohn’s disease. Little is known about the interaction of MSCs with drugs used in the treatment of fistulae in Crohn’s disease. We demonstrate here that on daily exposure to antibiotics commonly used in the management of fistulae (ciprofloxacin and metronidazole), as well as anti-TNFα (infliximab), mesenchymal stem cell retain their proliferation and differentiation capacity.

**Methods**

Cultured human bone marrow derived MSCs were plated at a density of 5×10⁴ cells per square centimeter in 24 well plates and allowed to adhere overnight. Cells were exposed to a range of daily doses of ciprofloxacin, metronidazole (0.1 µg/ml–50 µg/ml) and infliximab (1 µg/ml–500 µg/ml) for a 6-week period. MSC morphology was assessed daily and differentiation capacity into adipocyte, osteocyte and chondrocyte lineages was studied after exposure to the drugs. MSC survival was assessed at 6 weeks using Annexin-V Apodetect assay followed by FACS analysis. Cell survival was expressed as percentages of cells that were negative for Annexin-V and propidium iodide staining. Analyses were performed using the SPSS statistical package (V 19.0).

**Results**

MSCs exposed to a range of concentrations of ciprofloxacin, metronidazole and infliximab daily, consistently displayed a normal morphology as assessed by light microscopy. Following exposure of these drugs, differentiation into adipocyte, osteocyte and chondrocyte lineages was conserved. In the absence of drugs, mean survival (±SD) of MSCs was 81.8 ±8.6%. In the presence of ciprofloxacin, mean survival of MSCs was generally increased compared to control cells, significantly so at the highest concentration of 30 µg/ml: 90.1% (p<0.05). By contrast, with metronidazole and infliximab there was no suggestion of a change in survival level, when compared to control cells at any of the concentrations used.

**Conclusion**

This study demonstrates that, in vitro, morphological characteristics as well as the proliferation and differentiation capacity of MSCs is preserved in the presence of ciprofloxacin, metronidazole and infliximab. These findings are important in the consideration of the combination of MSCs with antibiotics and anti-TNFα therapy and will inform subsequent studies to optimise drug and cell delivery.

**RE-TREATMENT WITH INFlixIMAB AFTER A PROLONGED DRUG HOLIDAY IN PATIENTS WITH CROHN’S DISEASE**

doi:10.1136/gutjnl-2012-302514c.102

L Lee,* J Duncan, M Sastrillo, J Sanderson, P Irving. Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

**Introduction**

Infliximab (IFX) is a chimeric monoclonal antibody effective for inducing and maintaining remission in Crohn’s disease.
PTU-100 Developing Swansea inflammatory bowel disease clinical severity index (SICSI)

L Alrubaiy, J Williams and H Hutchings

*Gut* 2012 61: A225
doi: 10.1136/gutjnl-2012-302514c.100

Updated information and services can be found at:
http://gut.bmj.com/content/61/Suppl_2/A225.1

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/